Literature DB >> 10338464

Variant estrogen and progesterone receptor messages in human vascular smooth muscle.

Y K Hodges1, J K Richer, K B Horwitz, L D Horwitz.   

Abstract

BACKGROUND: Estrogens stimulate growth of breast or uterine cells but have the opposite effect on vascular smooth muscle cells, in which they protect against coronary artery disease with or without concomitant administration of progesterone. A possible cause of differences in hormone action is variable tissue-specific expression of hormone receptor. Therefore, we analyzed the structure of estrogen receptors (ERs) and progesterone receptors (PRs) in human vascular smooth muscle. METHODS AND
RESULTS: RNA was isolated from human vascular smooth muscle, and the functional domains of ER-alpha and PR were characterized by reverse transcriptase and polymerase chain reaction. Interestingly, in addition to wild-type ER-alpha and PR, 5 variant ER-alpha and 2 variant PR transcripts were found. These variants contained precise deletions of exons encoding regions of the hormone-binding domain. The PR transcripts lacked exon 4 (PRDelta4) and exon 6 (PRDelta6). The ER-alpha transcripts were missing exon 4 (ERDelta4), exon 5 (ERDelta5), exon 6 (ERDelta6), exon 7 (ERDelta7), and exons 6 and 7, (ERDelta6,7). ER-beta variants were also detected. The PR variants were functionally characterized, and PRDelta6 was found to be a dominant-negative transcription inhibitor of wild-type receptors. Variant PR was present in premenopausal women but absent in postmenopausal women.
CONCLUSIONS: Variant PR and ER transcripts are extensively expressed in human vascular smooth muscle. The complex tissue-specific effects of sex hormones may be mediated by the expression of heterogeneous forms of their cognate receptors. The presence of variant ERs and PRs may be of importance in altering the physiological effects of estrogens or progestins in vascular smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10338464     DOI: 10.1161/01.cir.99.20.2688

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  6 in total

Review 1.  From cellular to chemical approach for acute neural and alternative options for age-induced functional diseases.

Authors:  Antonin Bukovsky
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

2.  Estrogen deficiency accelerates progression of glomerulosclerosis in susceptible mice.

Authors:  Sharon J Elliot; Michael Karl; Mariana Berho; Mylene Potier; Feng Zheng; Baudouin Leclercq; Gary E Striker; Liliane J Striker
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

3.  Absence of mitochondrial progesterone receptor polymorphisms in women with spontaneous preterm birth.

Authors:  Tracy A Manuck; Thomas M Price; Elizabeth Thom; Paul J Meis; Mitchell P Dombrowski; Baha Sibai; Catherine Y Spong; Dwight J Rouse; Jay D Iams; Hyagriv N Simhan; Mary J O'Sullivan; Menachem Miodovnik; Kenneth J Leveno; Deborah Conway; Ronald J Wapner; Marshall Carpenter; Brian Mercer; Susan M Ramin; John M Thorp; Alan M Peaceman
Journal:  Reprod Sci       Date:  2010-08-06       Impact factor: 3.060

4.  Progesterone receptor expression in fibromuscular dysplasia: A report of two unusual cases.

Authors:  Murat Erkan; Şule Canberk; Mine Önenerk; Elif Sayman; Pembegül Güneş; Gökçen Orhan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2019-04-24       Impact factor: 0.332

5.  Expression and localization of estrogen receptor-alpha protein in normal and abnormal term placentae and stimulation of trophoblast differentiation by estradiol.

Authors:  Antonin Bukovsky; Maria Cekanova; Michael R Caudle; Jay Wimalasena; James S Foster; Donald C Henley; Robert F Elder
Journal:  Reprod Biol Endocrinol       Date:  2003-02-06       Impact factor: 5.211

Review 6.  Alternative splicing and the progesterone receptor in breast cancer.

Authors:  David M W Cork; Thomas W J Lennard; Alison J Tyson-Capper
Journal:  Breast Cancer Res       Date:  2008-05-30       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.